Colorectal Cancer Clinical Trial
Official title:
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy
Verified date | January 2016 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This 2 arm study will assess the efficacy and safety of intermittent oral Xeloda, or iv fluorouracil/leucovorin, in combination with intravenous Eloxatin (oxaliplatin) in patients previously treated for metastatic colorectal cancer. Patients will be randomized to receive either 1)XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2) FOLFOX-4 (oxaliplatin + leucovorin + 5-FU in 2 week cycles. The anticipated time on study treatment is until disease progression, and the target sample size is 500+ individuals.
Status | Completed |
Enrollment | 627 |
Est. completion date | August 2006 |
Est. primary completion date | August 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - adult patients >=18 years of age; - metastatic colorectal cancer; - >=1 target lesion; - failed first-line chemotherapy with 5-fluorouracil and irinotecan. Exclusion Criteria: - previous treatment with oxaliplatin; - progressive or recurrent disease during or within 6 months of completion of first-line chemotherapy; - >=1 previous chemotherapeutic agent or systemic anticancer regimen for metastatic disease. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States, Belgium, Canada, Croatia, Finland, France, Germany, Greece, Israel, Italy, Korea, Republic of, Poland, Puerto Rico, Serbia, Slovakia, Slovenia, South Africa, Spain, Taiwan, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival (PFS) | Progression free survival was defined as the time from the date of randomization to the day of documented disease progression or death from any cause. It was based on tumor assessments made according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment confirming that they had not progressed. Participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at date of randomization | Up to 3 years | No |
Secondary | Progression Free Survival Based on Independent Review Committee (IRC) Assessment | Progression free survival was defined as the time from the date of randomization to the day of documented disease progression or death from any cause. It was based on tumor assessments made according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria and was based on IRC assessment | Up to 3 years | No |
Secondary | Progression Free Survival Based on Treatment Analysis- ITT Population | Progression free survival was defined as the time from the date of randomization to the day of documented disease progression or death from any cause. It was based on tumor assessments made according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria and was based on treatment analysis. PFS analyzed using an on-treatment approach included only disease progression and death that occurred no later than 28 days after the last confirmed intake of study medication in the primary study treatment phase. | Up to 3 years | No |
Secondary | Progression Free Survival Based on Treatment Analysis-PP Population | Progression free survival was defined as the time from the date of randomization to the day of documented disease progression or death from any cause. It was based on tumor assessments made according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria and was based on treatment analysis. PFS analyzed using an on-treatment approach included only disease progression and death that occurred no later than 28 days after the last confirmed intake of study medication in the primary study treatment phase. | Up to 3 years | No |
Secondary | Best Overall Response (BOR), Investigators' Assessments | The best overall response in a participant was defined according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria as the best response recorded from the start of treatment until disease progression or recurrence (the reference for disease progression was the smallest measurement recorded since the baseline assessment). To be assigned a status of partial response (PR) or complete response (CR), changes in tumor measurements were confirmed by repeat assessments performed no fewer than 4 weeks after the criteria for response were first met. Only tumor assessments by the investigator up to and including 28 days after the last intake of study medication in the primary study treatment phase were considered for determining the best overall response of a participant. The analysis of best overall response was also performed using tumor assessments made by the Investigator | Up to 3 years | No |
Secondary | Best Overall Response (BOR), Independent Review Committee (IRC) Assessment | The best overall response in a participant was defined according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria as the best response recorded from the start of treatment until disease progression or recurrence (the reference for disease progression was the smallest measurement recorded since the baseline assessment). To be assigned a status of partial response (PR) or complete response (CR), changes in tumor measurements were confirmed by repeat assessments performed no fewer than 4 weeks after the criteria for response were first met. Only tumor assessments by the investigator up to and including 28 days after the last intake of study medication in the primary study treatment phase were considered for determining the best overall response of a participant. The analysis of best overall response was performed using tumor assessments made by the IRC. | Up to 3 years | No |
Secondary | Overall Survival | Overall survival was measured as the time from the date of randomization to the date of death. Participant who were not reported to have died at the time of the analysis were censored using the date they were last known to be alive. | Up to 3 years | No |
Secondary | Time To Response (TOR) | Time to response (best response of CR or PR) was measured as the time from randomization to the first date on which the measurement criteria for CR or PR (whichever status was recorded first) were met. | Up to 3 years | No |
Secondary | Duration Of Response (DOR) | Duration of response was defined as the time that measurement criteria were first met for CR or PR (whichever was recorded first) until the first date that progressive disease (PD) or death was documented. The data from participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants who neither progressed nor died were censored at the date of the last tumor assessment. For complete responders, the duration of CR was measured from the time measurement criteria for CR were first met until the date that PD (or death) was documented. | Up to 3 years | No |
Secondary | Time To Treatment Failure | Time to treatment failure was defined as the time from the date of randomization to the first occurrence of adverse event (AE), insufficient therapeutic response, death, failure to return, or refusing treatment/being uncooperative/withdrawing consent. | Up to 3 years | No |
Secondary | Number of Participants With Marked Post-baseline Laboratory Abnormalities by Trial Treatment | Laboratory abnormalities were defined as those values that were outside the Roche defined reference range and showed a clinically relevant change from baseline. All laboratory parameters were categorized according to the National Cancer Center Common Toxicity Criteria (NCI-CTCAE) grading system. Incidence of Grade 1 to 4 laboratory abnormalities are presented in the table below. | Up to 3 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |